Shares of ABIVAX Société Anonyme (ABVX) are down over 40% from their 52-week high of $14.16, recorded last July, to trade around $7.65.
This clinical-stage biotechnology company is focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. Its lead drug candidate is Obefazimod, being developed for the treatment of moderately to severely active ulcerative colitis (UC). Obefazimod is designed to enhance the expression of miR-124 and stabilize the immune response by downregulating key proteins associated with inflammation, such as IL-6 and TNF-alpha.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.